Impact Factor
4.21
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
5.47
2,807 total citations
h5-index
49
h5 depth signal
Cited share
85.3%
470 of 551
Total citations
2,807
Citation footprint
Metric signal
6.73
External metric anchor
Self-citation
0.5%
15 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
China
1,049
Italy
199
Iran
130
United States
92
Egypt
62
Citing Fields of Research
Immunology
456
Hematology
284
Oncology
232
Musculoskeletal Disorders
176
Cancer & Development
165
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
4,495
Articles tracked across the journal lifetime
Indexed publication set
551
470 cited publications
Last 12 months
463
38.6 publications/month
Open access share
100.0%
463 OA publications in the last year
Leading citing country
China
1,049 citing publications
Leading citing field
Immunology
456 citing publications
Latest tracked publication
19 October 2026
10 recent records available
Coverage & Indexing History
v1n1, Mar. 2001-
v1n1, Mar. 2001-
Active Coverage
Research Focus & Classification
Indexed Subjects
Immunology
Hematology
Noncoding RNA
Lymphomas
Oncology
Musculoskeletal Disorders
Liver & Colon Cancer
Broad Categories
Medicine
Immunology
Lymphomas
Noncoding RNA
Hematology
Musculoskeletal Disorders
Auto-Inflammatory Disorders
MeSH Descriptors
Clinical Medicine
Research
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1007/s10238-026-02362-6
Open DOI
An actively regenerating hematopoietic environment enhances the function of transplanted stem cells
02
03
DOI 10.1007/s10238-026-02357-3
Open DOI
tRF-Gln-CTG-7 promotes AML cell growth and survival through AGGF1 and is associated with poor prognosis
04
05
DOI 10.1007/s10238-026-02311-3
Open DOI
Oncolytic virotherapy for cancer: biological mechanisms, clinical advances, and future perspectives
Oncolytic virotherapy has emerged as a promising cancer treatment that combines selective tumor destruction with potent stimulation of antitumor immunity. Unlike conventional therapies, oncolytic viruses (OVs) preferentially infect and r...
06
DOI 10.1007/s10238-026-02343-9
Open DOI
Inflammasome, clonal stability and the thrombotic circuit in myeloproliferative neoplasms: an antecedent framework
El-Sehrawy and colleagues recently proposed a model of clonal thrombo-inflammation in myeloproliferative neoplasms organised around the inflammasome, clonal stability and a multi-compartmental thrombotic niche. Each of these elements was...
07
DOI 10.1007/s10238-026-02348-4
Open DOI
Advancing precision oncology: a critical review of in Silico tools for nanoparticle-based drug delivery systems
08
DOI 10.1007/s10238-026-02347-5
Open DOI
Extrachromosomal DNA and cell-free DNA in breast cancer liquid biopsy: current evidence and future perspectives
09
DOI 10.1007/s10238-026-02325-x
Open DOI
Exploratory single-cell profiling of intrarenal B and T cell subsets in ANCA-associated glomerulonephritis
10
DOI 10.1007/s10238-026-02326-w
Open DOI
Mitochondrial governance of antitumour immunity: mechanisms and therapeutic exploration
Bibliographical & Catalog Notes
Title from cover.
Print issues ceased with v. 11, no. 4 (2011).
Also available online.
Merger of: International journal of clinical & laboratory research; and: Research in experimental medicine.